Dashboard
Manage Tickers

GILD


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cvs-health-delivers-confident-outlook-after-q3-performance-stock-hits-52-week-high
CVS Health Delivers Confident Outlook Afte...
10/29/2025 14:20:39

CVS Health topped Q3 estimates with $102.9 billion in revenue and raised its 2025 EPS outlook to up to $6.65 amid strong segmen...

a-glimpse-of-gilead-sciencess-earnings-potential
A Glimpse of Gilead Sciences's Earnings Po...
10/29/2025 14:04:23

update-fda-approves-kite-pharmas-yescarta-bla-supplement-allowing-short-term--80c-storage-for-up-to-90-days-at-authorized-treatment-centers-supplement-approval-was-on-october-21-2025
UPDATE: FDA Approves Kite Pharma's Yescart...
10/28/2025 15:46:08

https://www.fda.gov/media/189364/download?attachment

fda-approves-kites-yescarta-for-treatment-of-adults-with-large-b-cell-lymphoma-that-is-refractory-to-first-line-chemoimmunotherapy
FDA Approves Kite's Yescarta For Treatment...
10/28/2025 15:19:56

-Reuters

if-you-invested-1000-in-gilead-sciences-stock-20-years-ago-you-would-have-this-much-today
If You Invested $1000 In Gilead Sciences S...
10/27/2025 14:45:17

retail-investors-top-stocks-with-earnings-this-week-sofi-apple-meta-and-more
Retail Investors' Top Stocks With Earnings...
10/27/2025 14:38:22

Investors are gearing up for a jam-packed week of earnings featuring several big tech names and retail-trader favorites. 

td-cowen-maintains-buy-on-gilead-sciences-raises-price-target-to-125
TD Cowen Maintains Buy on Gilead Sciences,...
10/23/2025 15:31:32

TD Cowen analyst Tyler Van Buren maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $115 to...

gilead-sciences-to-present-new-research-reinforcing-commitment-to-advancing-innovation-for-people-living-with-liver-disease-at-the-liver-meeting-2025
Gilead Sciences To Present New Research Re...
10/23/2025 12:05:43

- Late-Breaking Real-World Experience of People Switching from Obeticholic Acid to Livdelzi® to be Presented atThe Liver Meetin...

gilead-wins-health-canada-approval-for-new-liver-disease-drug-lyvdelzi-offering-relief-to-patients-with-limited-treatment-options
Gilead Wins Health Canada Approval For New...
10/21/2025 11:04:01

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Health Canada has approved LYVDELZI (seladelpar) for the treatment of ...

reported-sunday-gilead-sciences-phase-3-ascent-03-study-shows-trodelvy-cut-risk-of-disease-progression-or-death-by-38-versus-chemotherapy-in-first-line-metastatic-triple-negative-breast-cancer
Reported Sunday, Gilead Sciences' Phase 3 ...
10/20/2025 07:47:49

– Late-Breaking ASCENT-03 Data Simultaneously Presented at ESMO 2025 and Published in The New England Journal of Medicine –– Wi...

reported-sunday-gilead-showcases-34-presentations-including-six-oral-sessions-across-hiv-respiratory-viruses-viral-hepatitis-pandemic-pathogens-at-idweek
Reported Sunday, Gilead Showcases 34 Prese...
10/20/2025 07:29:52

– Additional Phase 3 PURPOSE Data Reinforce the Safety Profile of Twice-Yearly Yeztugo® as an Effective HIV Prevention Option A...

uk-health-agency-recommends-gsk-backed-viiv-healthcares-apretude-as-injectable-hiv-treatment
UK Health Agency Recommends GSK-Backed Vii...
10/17/2025 16:43:32

NICE recommends ViiV Healthcare's Apretude as the first injectable PrEP for HIV prevention, offering an alternative to dail...

mercks-new-hiv-treatment-works-as-well-as-top-drug-in-late-trials
Merck's New HIV Treatment Works As Well As...
10/15/2025 16:23:05

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase ...

gilead-presents-latest-clinical-data-on-lenacapavir-biktarvy-and-novel-long-acting-hiv-combinations-at-eacs-2025
Gilead Presents Latest Clinical Data On Le...
10/15/2025 07:56:04

 New Data Showcase Safety Profile of Twice-Yearly Lenacapavir for Pre-Exposure Prophylaxis (PrEP) with Other Medications and Re...

gilead-sciencesarcus-biosciences-investigational-cancer-drug-shows-overall-survival-of-around-27-months
Gilead Sciences/Arcus Biosciences' Investi...
10/13/2025 14:33:57

Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combinatio...

gilead-coinbase-rocket-lab-and-a-tech-stock-on-cnbcs-final-trades
Gilead, Coinbase, Rocket Lab And A Tech St...
10/13/2025 12:32:20

On CNBC's "Halftime Report Final Trades," Rob Sechan, CEO of NewEdge Wealth, named Gilead Sciences as his final trade.

Core News & Articles
CNBC Halftime Report Final Trades: Gilead...
10/10/2025 17:01:36

breaking-down-gilead-sciences-6-analysts-share-their-views
Breaking Down Gilead Sciences: 6 Analysts ...
10/08/2025 22:01:01

citigroup-maintains-buy-on-gilead-sciences-raises-price-target-to-135
Citigroup Maintains Buy on Gilead Sciences...
10/08/2025 18:33:25

Citigroup analyst Geoff Meacham maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $125 to ...

heres-how-much-you-would-have-made-owning-gilead-sciences-stock-in-the-last-20-years
Here's How Much You Would Have Made Owning...
10/07/2025 23:45:27

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION